FY2028 EPS Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX) Cut by Analyst

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Travere Therapeutics in a report released on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of $4.29 for the year, down from their previous forecast of $4.66. HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share.

A number of other analysts have also commented on the company. Wells Fargo & Company lifted their price target on Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Wedbush reissued an “outperform” rating and set a $13.00 price target on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Piper Sandler lifted their price target on Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, January 18th. Finally, Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $5.39 on Thursday. The business’s 50-day moving average price is $7.34 and its 200-day moving average price is $7.66. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $22.75. The firm has a market capitalization of $410.23 million, a price-to-earnings ratio of -3.35 and a beta of 0.58. The company has a current ratio of 3.47, a quick ratio of 3.41 and a debt-to-equity ratio of 1.88.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.11. The business had revenue of $45.06 million for the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its holdings in shares of Travere Therapeutics by 9.6% during the third quarter. Teacher Retirement System of Texas now owns 18,804 shares of the company’s stock valued at $168,000 after acquiring an additional 1,641 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Travere Therapeutics by 9.7% during the fourth quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock valued at $189,000 after acquiring an additional 1,851 shares in the last quarter. Signaturefd LLC boosted its position in shares of Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after buying an additional 2,849 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Travere Therapeutics by 7.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company’s stock valued at $417,000 after buying an additional 3,083 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in shares of Travere Therapeutics by 4.5% during the first quarter. Rice Hall James & Associates LLC now owns 73,400 shares of the company’s stock valued at $566,000 after buying an additional 3,140 shares during the last quarter.

Insiders Place Their Bets

In other Travere Therapeutics news, CEO Eric M. Dube sold 19,122 shares of Travere Therapeutics stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.70, for a total value of $166,361.40. Following the completion of the sale, the chief executive officer now directly owns 350,600 shares in the company, valued at $3,050,220. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP William E. Rote sold 4,764 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total transaction of $41,494.44. Following the completion of the sale, the senior vice president now owns 80,720 shares in the company, valued at $703,071.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Eric M. Dube sold 19,122 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.70, for a total value of $166,361.40. Following the sale, the chief executive officer now owns 350,600 shares of the company’s stock, valued at approximately $3,050,220. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,773 shares of company stock worth $300,625. 3.75% of the stock is owned by corporate insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.